NM504
Phase 1- Indications
- Prediabetes
Company intelligence / Profile preview
NuMe Health
New Orleans, Louisiana, United Statesnumehealthcoaching.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Phase 1
01
Overview
NuMe Health developed evidence-based prebiotic/cobiotic products targeting the gut microbiome to manage metabolic health, with lead product NM504 tested in clinical trials for type 2 diabetes and insulin sensitivity. The company later rebranded as MicroBiome Therapeutics.[3] No recent clinical results are available under the original name.
- Therapeutic areas
- OncologyEndocrinologyMetabolic Disorders
- Modalities
- Prebiotics (cobiotic™ products)Medical foods
- Industry
- Non-Drug Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on NuMe Health.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NuMe Health.